Summary of Key Points Core Viewpoint - On August 29, 2023, Guizhou Moutai announced plans for significant stock buybacks, while 13 other listed companies disclosed their intentions to reduce shareholdings, indicating a mixed sentiment in the market regarding stock ownership adjustments [1][2]. Group 1: Stock Buybacks - Guizhou Moutai's controlling shareholder intends to increase their stake by purchasing between 3 billion to 3.3 billion yuan worth of company shares [2]. Group 2: Stock Reductions - Several companies announced share reductions, including: - Sayi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce holdings by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their holdings by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce holdings by up to 0.0615% [2]. - Aoyue Technology: Tian Tai Bolong plans to reduce holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce holdings by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce holdings by up to 1% [2].

Core Viewpoint - BioVeda plans to reduce its stake in Aojing Medical (688613.SH) by up to 1,355,515 shares, representing 1% of the total shares, due to its own financial arrangements [1] Group 1 - Aojing Medical has received a notification from BioVeda regarding its share reduction plan [1] - The reduction will be executed through centralized bidding and block trading based on market conditions [1] - The total number of shares BioVeda intends to sell is capped at 1,355,515 [1]

Group 1 - The company, Aojing Medical Technology Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 on September 15, 2025, at 14:30 [3][5] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange's shareholder meeting voting system [2][3] - Shareholders must register by September 11, 2025, to attend the meeting, and specific documentation is required for different types of shareholders [4][5] Group 2 - The meeting will review non-cumulative voting proposals, with the first proposal already approved by the company's board [1][3] - The network voting will be available from 9:15 to 15:00 on the day of the meeting, with specific time slots for trading system voting [3][4] - There are no related shareholders that need to abstain from voting [2]

Core Viewpoint - The company plans to temporarily use part of its idle raised funds, not exceeding RMB 30 million, to supplement its working capital while ensuring that the investment projects are not affected [2][4][5] Summary by Sections 1. Basic Situation of Raised Funds - The company issued 33,333,334 shares at a price of RMB 16.43 per share, raising a total of RMB 547,666,677.62 [1] - The total issuance costs amounted to RMB 49,653,236.30, including various fees [1] 2. Situation of Investment Projects - The company has a total of RMB 500,816,900.00 planned for investment in projects related to bone regeneration and artificial bone repair materials [2] - As of June 30, 2025, the unused balance of raised funds was RMB 819,299,209.1 (including interest) [2] 3. Plan for Using Idle Funds - The company intends to use up to RMB 30 million of idle raised funds for working capital, with a usage period not exceeding 12 months [2][3] - The funds will only be used for business expansion and daily operations related to the main business [3] 4. Review Procedures and Special Opinions - The board of directors and the supervisory board approved the use of idle funds, which does not require shareholder meeting approval [4] - The supervisory board believes this action will meet the company's working capital needs and improve the efficiency of idle fund usage [4] 5. Sponsor's Verification Opinion - The sponsor confirmed that the company followed necessary approval procedures and that the use of idle funds will not affect the investment projects [4][5]

Group 1 - The company plans to use part of the raised funds to increase capital in its wholly-owned subsidiary, Beijing Aojing Medical Equipment Co., Ltd., for the implementation of fundraising projects [1][2] - The total amount of funds raised is approximately RMB 547.67 million, with a net amount of RMB 500.82 million after deducting issuance costs [1][2] - The capital increase will amount to RMB 9.77 million, raising the registered capital of Beijing Aojing Medical Equipment from RMB 39.00 million to RMB 48.77 million, maintaining 100% ownership [2][3] Group 2 - The fundraising projects include the development of guided bone regeneration membranes, artificial bone powder, and mineralized collagen artificial bone repair materials targeted at the U.S. market [2] - The company has established a dedicated account for the raised funds and will implement strict regulatory measures to ensure the safety of the funds [5][6] - The board of directors and the supervisory board have approved the capital increase, which does not require shareholder meeting approval, and complies with relevant regulations [6]

证券代码：688613 证券简称：奥精医疗 公告编号：025-045 奥精医疗科技股份有限公司 第二届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 奥精医疗科技股份有限公司（以下简称"公司"）第二届监事会第十四次会 议于 2025 年 8 月 29 日以现场表决的方式召开。会议通知已通过邮件的方式送达 各位监事。本次会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席吴 永强主持。会议的召集和召开程序符合有关法律、法规、规章和《奥精医疗科技 股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事认真审议，做出如下决议： （一）审议通过《<2025 年半年度报告>及其摘要的议案》 经审议，公司监事会全体监事认为公司《2025 年半年度报告》的编制和审 议程序符合相关法律法规、《公司章程》及公司内部管理制度的各项规定；公司 《2025 年半年度报告》的内容与格式符合中国证券监督管理委员会和上海证券 交易所的各项规定，公允地反映了公司 ...

经中国证券监督管理委员会证监许可[2021]1219号《关于同意奥精医疗科 技股份有限公司首次公开发行股票注册的批复》批准，并经上海证券交易所同 意，公司向社会公开发行人民币普通股（A股）股票3,333.3334万股，每股发行 1 价格16.43元，募集资金总额为人民币547,666,677.62元，扣除不含税的发行费 用后募集资金净额为人民币500,816,913.05元。公司上述募集资金已于2021年5 月17日到账。以上募集资金到位情况，已经立信会计师事务所（特殊普通合伙） 验证，并出具了首次发行《验资报告》（信会师报字[2021]第ZB11115号）。公 司已在银行开设了专户存储上述募集资金。 | 序 号 | 开户银行 | 银行账号 | | --- | --- | --- | | 1 | 招商银行股份有限公司北京大兴支 行 | 110905742010908 | | 2 | 招商银行股份有限公司北京大兴支 行 | 110905742010803 | | 3 | 招商银行股份有限公司北京大兴支 行 | 110905742010206 | | 4 | 招商银行股份有限公司北京大兴支 行 | 1109278 ...

关于公司非独立董事、总经理辞职暨补选非独立董 事、聘任总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开 了第二届董事会第十五次会议，审议通过了《关于公司非独立董事、总经理辞职 暨补选非独立董事、聘任总经理的议案》。具体情况如下： 一、 公司董事、总经理的辞职情况 奥精医疗科技股份有限公司（以下简称"公司"）董事会于近日收到公司非 独立董事、总经理崔孟龙先生提交的辞呈。崔孟龙先生因个人原因，申请辞去公 司非独立董事、总经理职务，辞任后崔孟龙先生将不在公司及子公司担任任何职 务。 根据相关法律规定，崔孟龙先生的辞呈自送达董事会之日起生效，其辞职不 会导致公司董事会人数低于法定最低人数，公司将尽快按照法定程序完成董事补 选工作。 证券代码：688613 证券简称：奥精医疗 公告编号：2025-047 奥精医疗科技股份有限公司 仇志烨先生在通过公司股东大会选举为非独立董事后将接任崔孟龙先生原 担任的公司第二届董事会战略与发展委员会委员职 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-041 2025 年半年度募集资金存放、管理与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可[2021]1219 号《关于同意奥精医疗科 技股份有限公司首次公开发行股票注册的批复》批准，并经上海证券交易所同意， 本公司向社会公开发行人民币普通股（A 股）股票 3,333.3334 万股，每股发行 价格 16.43 元，募集资金总额为人民币 547,666,677.62 元，扣除不含税的发行 费用后募集资金净额为人民币 500,816,913.05 元。公司上述募集资金已于 2021 年 5 月 17 日到账。以上募集资金到位情况，已经立信会计师事务所（特殊普通 合伙）验证，并出具了首次发行《验资报告》（信会师报字[2021]第 ZB11115 号）。公司在银行开设了专户存储上述募集资金。 （二）募集资金使用和结余情况 奥精医疗科技股份有限公 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、为提高募集资金使用效率，经奥精医疗科技股份有限公司（以下简称 "公司"）第二届董事会第十五次会议及第二届监事会第十四次会议审议通过， 公司拟使用总额不超过人民币3,000.00万元（含3,000.00万元）的闲置募集资 金暂时补充流动资金，并仅用于公司的业务拓展、日常经营等与主营业务相关 的生产经营活动。 2、公司拟使用部分闲置募集资金暂时补充流动资金的期限自董事会审议 通过之日起不超过 12 个月，到期将及时归还至募集资金专用账户。 公司于2025年8月29日召开第二届董事会第十五次会议及第二届监事会第十 四次会议审议通过了《关于公司使用部分闲置募集资金暂时补充流动资金的议 案》，同意根据募集资金投资项目的资金使用计划及项目的建设进度，公司在确 保不影响募集资金投资项目建设进度的前提下，为了提高募集资金使用效率，降 低公司财务成本，使用部分闲置募集资金暂时补充流动资金。现将相关事项公告 如下： 证券代码： 688613 证券简称：奥精医疗 公告编号： 2025-042 ...